A.B. Tulyayeva¹, E.M. Iztleuov¹, A.K. Koishybaev¹, P.A. Aitmagambet¹, N.M. Imanbayev¹, G.A. Zhurabekova¹, G.A. Batyrova¹, D.A. Zholmukhamedova¹, N.M. Kereeva¹, M.A. Aitmagambetova¹

1. «Marat Ospanov West Kazakhstan Medical University» NСJSC, Aktobe, the Republic of Kazakhstan

DOI: https://www.doi.org/10.52532/2521-6414-2024-1-71-35-39

UDC: 616.33-006.6-07:577

Year: 2024 issure: 71 number: 1 pages: 35-39

Download PDF:

ABSTRACT

Relevance: Colorectal cancer (CRC), arising from the right-sided or left-sided colon, is a separate clinical and pathological unit. The status of KRAS and its predictive value in CRC remain controversial.
The study aimed to explore the effect of primary tumor localization on KRAS gene status in CRC.
Methods: The study included 60 patients with colon and rectal cancer. The KRAS mutation test was performed on paraffin-coated tumor samples using PCR methods. Colon cancer was divided into right-sided colon cancer (RSCC) and left-sided colon cancer (LSCC).
Results: KRAS mutation was found much more often in rectal cancer (RC) and sigmoid colon (SC) (p=0.413) than in tumors in other parts of the colon. A combined analysis of our data and previously published data showed that KRAS mutation was more common in PSTC, especially in the area of the hepatic bend of the colon than in LSTC (p=0.120). The association of the KRAS mutation with the patient’s age (p<0.012) and the duration of hospitalization (p<0.001) was established.>
Conclusion: Our study revealed no significant difference in the KRAS status between colon cancer and rectal cancer. However, KRAS mutation was much more common in RSCC compared to LSCC. Patients with RSCC with mutated KRAS also had a worse prognosis and required longer hospitalization compared to wild-type KRAS. However, patients with LSCC did not demonstrate a similar effect.
Keywords: colon cancer, rectal cancer, sigmoid cancer, KRAS mutation.

List of sources used:

1. World Health Organization. International Agency for Research on Cancer. Globocan 2020. Kazakhstan fact sheets. 02.11.23. https://gco.iarc.fr/today/data/factsheets/populations/398-kazakhstan-fact-sheets.pdf
2. World Health Organization. International Agency for Research on Cancer. Estimated number of new cases from 2020 to 2040, Incidence, Both sexes, age [0-85+] Kazakhstan. 06.11.2023. https://gco.iarc.fr/tomorrow/en/dataviz/tables?types=0&sexes=0&mode=cancer&group_populations=1&multiple_populations=0&multiple_cancers=1&cancers=7&populations=398&years=2030
3. Moehler M., Högner A., Wagner A. D., Obermannova R., Alsina M., Thuss-Patience P., van Laarhoven H., Smyth E. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma //Eur. J. Cancer. – 2022. – Vol. 176. – P. 13-29. https://doi.org/10.1016/j.ejca.2022.08.023
4. Ye Z., Shi Y., Lees-Miller S.P., Tainer J.A. Function and Molecular Mechanism of the DNA Damage Response in Immunity and Cancer Immunotherapy // Front. Immunol. – 2021. – Vol.12. – Art. no. 797880. https://doi.org/10.3389/fimmu.2021.797880
5. Dietlein F., Thelen L., Reinhardt H.C. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches // Trends Genet. – 2014. – Vol. 30. – P. 326-339. https://doi.org/10.1016/j.tig.2014.06.003
6. O’Connor M.J. Targeting the DNA damage response in cancer // Mol. Cell. – 2015. – Vol. 60. – P. 547–560. https://doi.org/10.1016/j.molcel.2015.10.040
7. Stope M.B. Phosphorylation of histone H2A.X as a DNA‑associated biomarker (Review) // World Acad. Sci. J. – 2021. – Vol. 3. – P. 31. https://doi.org/10.3892/wasj.2021.102
8. Sekiguchi M., Matsushita N. DNA Damage Response Regulation by Histone Ubiquitination // Int. J. Mol. Sci. – 2022. – Vol. 23 (15). – P. 8187. https://doi.org/10.3390/ijms23158187
9. Banjarnahor C.T.U., Hardiany N.S., Wahjoepramono E.J., Hariyanto A.D., Sadikin M. High concentration of γ‑H2AX correlates with a marker of apoptotic suppression and PI3K/Akt pathway upregulation in glioblastoma multiforme // Oncol. Lett. – 2023. – Vol. 25 (4). – Art. no. 149. https://doi.org/10.3892/ol.2023.13735
10. Zamperone A., Cohen D., Stein M., Viard C., Müsch A. Inhibition of polarity-regulating kinase PAR1b contributes to Helicobacter pylori inflicted DNA Double Strand Breaks in gastric cells // Cell. Cycle. – 2019. – Vol. 3. – P. 299-311. https://doi.org/10.1080/15384101.2018.1560121
11. Kim J.H., Kim S.S., Byun S.W., Chang Y.J., Kim J.S., Kim J.K., Cho H.J., Lim K.W., Jung E.S. Double strand break of DNA in gastric adenoma and adenocarcinoma // Korean J. Gastroenterol. – 2010. – Vol. 55 (1). – P. 19-25. https://doi.org/10.4166/kjg.2010.55.1.19
12. Xie C., Xu L.Y., Yang Z., Cao X.-M., Li W., Lu N.-H. Expression of γH2AX in various gastric pathologies and its association with Helicobacter pylori infection // Oncol. Lett. – 2014. – Vol. 7 (1). – P. 159-163. https://doi.org/10.3892/ol.2013.1693